| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Neuralink | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.34B | Series E | 6/2/2025 | $649M | $9.65B | $50.50 | ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed Venture Partners, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners, Vy Capital, K2 Global, K5 Global, Goanna Capital, Integra Groupe, LDV Partners, Mac Equity, Moonshots Capital, Neman Family Office, Pittco Management, POLYInvest, Realm Capital Ventures, Selective VC, Seven Rivers Capital, Talok Capital, Team Ignite Ventures, Transform Investments, Trousdale Ventures, Unmatched Ventures, Vibhu Venture Partners, VU Venture Partners | ||||
 | Life Biosciences | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $349.90K | -- | 2 | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | OURA | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.65B | Series E | 10/14/2025 | $900M | $11B | $53.57 | Fidelity, ICONIQ, Whale Rock Capital, Atreides, Lateralus Holdings, Matter Venture Partners | ||||
 | ZocDoc | Healthcare Digital Health | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | $5.00 | +0.00% | +0.00% | $1.15B | Series D-2 | 2/11/2021 | $100M | $2.62B | $29.29 | Francisco Partners | ||||
 | Abridge | Healthcare Healthcare Software | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $100.13K | -- | 1 | -- | $174.83 | -0.60% | +10.32% | $773.91M | Series E | 6/24/2025 | $315.93M | $5.3B | $158.48 | Andreessen Horowitz, Khosla Ventures, Archerman Capital, California Health Care Foundation, Catalio Capital Management, Eli Lilly, Emerson Collective, Harper Ventures, Soma Capital, WndrCo | ||||
 | Isomorphic Labs | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $200.05K | -- | 2 | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Altos Labs | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $100.01K | -- | 1 | Not available | -- | -- | $11.13B | Series C | 2/14/2024 | $1.5B | $6.33B | $25.02 | Undisclosed Investors | ||||
 | Spring Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $570.61M | Series D Aegis | 4/30/2026 | $130M | $3.52B | $69.22 | Undisclosed Investors | ||||
 | Latigo Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $287.9M | Series B | 3/17/2025 | $150M | $525.73M | $1.57 | Blue Owl Capital, Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, Kern Capital, Westlake Village BioPartners, Foresite Capital, 5AM Ventures, Alexandria Venture Investments | ||||
 | Collective Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | $0.18 | +0.00% | -10.00% | $713.28M | Series F | 5/4/2021 | $280M | $1.53B | $0.75 | HCSC, DFJ Growth, Founders Fund, G Squared, Maverick Ventures, NEA, PFM Health Sciences, SoftBank, Sun Life Financial | ||||
 | Apnimed | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $249.52M | Series D-1 | 3/11/2026 | $25M | $491.51M | $13.03 | Undisclosed Investors | ||||
 | Colossal Biosciences | Healthcare Biotech & Pharma | Medium | $xx.xx | $xx.xx | $xx.xx | xx% | $360.00K | -- | 1 | -- | Not available | -- | -- | $620.64M | Series C | 2/3/2026 | $380M | $10.32B | $24.89 | TWG Global, Peter Jackson, US Innovative Technology Fund, Robert Nelsen, United Arab Emirates | ||||
 | Cresilon | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $102.50K | -- | 1 | -- | Not available | -- | -- | $155.82M | Series A-6 | 7/20/2026 | $29M | $247.14M | $0.85 | Undisclosed Investors | ||||
 | Generate Biomedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $812.92M | Series C | 1/21/2025 | $399.4M | $2.22B | $11.85 | Amgen, Nvidia, MAPS Capital, Pictet Alternative Advisors, Flagship Pioneering, Abu Dhabi Investment Authority, Fidelity, T. Rowe Price, ARCH Venture Partners, March Capital, Alaska Permanent Fund, Altitude Life Science Ventures, Novartis | ||||
 | Calm | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $442.28M | Series 1 | 2/29/2024 | $25.07M | $404.67M | $2.38 | Undisclosed Investors | ||||
 | Function Health | Healthcare Digital Health | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $521.18M | Series B-2 | 7/30/2026 | $94.11M | $2.94B | $92.23 | Undisclosed Investors | ||||
 | Virta Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $395.18M | Series F | 12/29/2025 | $30.15M | $1.2B | $1.46 | Undisclosed Investors | ||||
 | Insilico Medicine | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Tempus | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $3.06B | Series G-5 | 4/30/2024 | $200M | $8.89B | $57.31 | Softbank | ||||
 | OpenEvidence | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $893.23M | Series D-2 | 4/14/2026 | $192.5M | $12.19B | $487.38 | Undisclosed Investors | ||||
 | Precision Neuroscience | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $6.5M | -- | 6 | Not available | -- | -- | $182.65M | Series C | 12/16/2024 | $102M | $542.69M | $5.70 | General Equity Holdings, B Capital, Duquesne Family Office, Steadview Capital | ||||
 | Synchron | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $2.99M | -- | 1 | Not available | -- | -- | $318.41M | Series D | 11/6/2025 | $200M | $821.5M | $36.70 | Double Point Ventures, ARCH Venture Partners, Khosla Ventures, Bezos Expeditions, NeuroTechnology Investors, METIS, National Reconstruction Fund Corporation, T.Rx Capital, QIA, K5 Global, Protocol Labs, IQT | ||||
 | Xaira Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1B | Series A | 4/23/2024 | $500M | $2.65B | $2.50 | ARCH Venture Partners, Foresite Capital, F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures, Parker Institute for Cancer Immunotherapy, Byers Capital, Rsquared, SV Angel, AIM13, Breyer Capital, Deviation Capital, Foresite Labs, JSL Health Capital, Longwood Fund, Sahsen Ventures, WRF Capital | ||||
 | Included Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $529.32M | Series E | 9/9/2020 | $103.04M | $1.13B | $3.22 | The Carlyle Group | ||||